Drug Profile
HT 0712
Alternative Names: HT-0712; IPL-455903Latest Information Update: 31 Jul 2019
Price :
$50
*
At a glance
- Originator Inflazyme Pharmaceuticals
- Developer Dart NeuroScience
- Class Anti-inflammatories; Cyclopentanes; Nootropics; Phenyl ethers; Piperidones; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Memory disorders
Most Recent Events
- 31 Jul 2019 Phase II development is ongoing in USA and Europe (Dart Neuroscience pipeline, July 2019)
- 29 Jul 2015 Phase-II development is ongoing in USA and Europe
- 01 Jan 2015 Dart NeuroScience completes a phase II trial in Memory disorders in USA (NCT02013310)